Program Plus Tablets cntain the active ingredients: milbemycin oxime and lufenuron. These coated tablets are available in 3 different sizes: 115mg, 230mg and 460mg.

Program Plus tablets are indicated for the prevention of fleas (Ct. felis, Ct. canis, preadult stages), and for the concurrent prevention of heartworm disease (elimination of 3rd and 4th larval stages of Dirofilaria immitis) and/or treatment of adult stages of gastrointestinal nematodes such as hookworms (Ancylostoma caninum), roundworms (Toxocara canis) and whipworms (Trichuris vulpis) in dogs.

Green outer pack, tablets contain: 5.75mg milbemycin oxime and 115mg lufenuron

Yellow outer pack, tablets contain: 11.5mg milbemycin oxime and 230mg lufenuron

White outer pack, tablets contain: 23mg milbemycin oxime and 460mg lufenuron.

Program Plus tablets are administered at a minimum dose of 0.5 mg milbemycin oxime and 10 mg lufenuron per kg body weight. Program Plus tablets are available in four sizes and are given according to the weight of the dog.

For dogs greater than 45 kg, a combination of tablets is given, consistent with the recommended minimum dose. Program Plus tablets should be administered in the following situations: Puppies To prevent flea infestations with concurrent heartworm prevention and/or gastrointestinal nematode infection medication should start from 2 weeks of age, or from a minimum weight of 1 kg.

Program Pluscan be used as part of the seasonal prevention of fleas replacing lufenuron mono (Program tablets) in cases with diagnosed concurrent gastrointestinal nematode infection. After elimination of the nematode infection confirmed by faecal examination, prevention of fleas should continue with Program tablets if indicated.

In puppies, medication with Program Plus is recommended up to one month after weaning. Thereafter, prevention of fleas can be continued with lufenuron mono (Program).

To prevent flea infestations and heartworm disease at the same time, dogs travelling to a heartworm risk region should begin medication within one month after arrival. Treatment should continue monthly, with the last administration given after the dog has left the region.

Dogs in a heartworm region:To prevent flea infestations and heartworm disease at the same time, medication should begin within one month after the appearance of mosquitoes, or one month before the appearance of fleas, and continue throughout the risk period with the last dose given within one month after the mosquito and flea season finishes.

If dogs have a high level of flea infestation at the start of treatment, it may be necessary to apply a flea adulticide during the first one to two months. It is important to treat all dogs and cats in the household for fleas. Cats in the same household should be treated with Program oral or injectable suspension.

To ensure adequate drug absorption, Program Plus tablets must be administered with food (for example mixed with the daily feed) or placed directly in the mouth after feeding.

Treatment with Program Plus tablets may begin at any time of the year. In geographic areas where the presence of fleas and mosquitoes (heartworm vector) is seasonal, depending on ambient temperature, treatment should be started one month prior to the appearance of the insects and then repeated monthly throughout the risk period. In environments with year-round flea infestations and concurrent heartworm risk, treatment may be continued throughout the year without interruption.

Ideally, tablets are administered on the same day each month. If an interval is greater than 6 weeks, treatment should be resumed immediately and be continued at monthly intervals and, in case of heartworm prevention, a veterinarian should be consulted.

Program Plus tablets immediately block the reproductive cycle of fleas by inhibiting the development of eggs and larvae. Pre-existing generations (e.g. pupae) present in the environment can, however, continue to develop and emerge for several weeks after the start of treatment.

In heartworm risk regions, or if it is known that a dog has been travelling to and from heartworm risk regions, before commencing PROGRAM PLUS treatment as with any other heartworm preventive, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering PROGRAM PLUS.

Pale mucous membranes and increased intestinal peristalsis have been observed in some dogs after treatment. The treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of moderate and transitory hypersensitivity reactions, such as pale mucous membranes, vomiting, laboured breathing, or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product.

If you notice any other side effects, please inform your veterinary surgeon.

To be sold on presentation of a veterinary prescription only. Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived from such Veterinary Medicinal Products. Any unused Program Plus tablets or waste materials derived from them should be disposed of in accordance with national requirements.

Keep out of the reach and sight of children. Do not store above 25°C.

Milbemycin oxime, which belongs to the group of macrocyclic lactones, is active against mites, against larval and adult stages of nematodes as well as against larvae of Dirofilaria immitis.

No alteration of reproductive function, neither foetal nor neonatal toxicity has been reported for lufenuron and milbemycin oxime used as a monotherapy in dogs.